Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.140
+0.020 (+1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
August 27, 2024
Via
ACCESSWIRE
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
August 20, 2024
Via
ACCESSWIRE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
August 19, 2024
Via
ACCESSWIRE
Jaguar Health Reports Second Quarter 2024 Financial Results
August 13, 2024
Via
ACCESSWIRE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
August 12, 2024
Via
ACCESSWIRE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
August 05, 2024
Via
ACCESSWIRE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
July 31, 2024
Via
ACCESSWIRE
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
June 26, 2024
Via
ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
June 21, 2024
Via
ACCESSWIRE
Jaguar Health, Inc. Announces Reverse Stock Split
May 17, 2024
Via
ACCESSWIRE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
August 02, 2024
Via
ACCESSWIRE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
August 01, 2024
Via
ACCESSWIRE
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
July 23, 2024
Via
ACCESSWIRE
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
July 18, 2024
Via
ACCESSWIRE
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
July 08, 2024
Via
ACCESSWIRE
Jaguar Health Reports First Quarter 2024 Financial Results
May 14, 2024
Via
ACCESSWIRE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
May 13, 2024
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
May 08, 2024
Via
ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
April 09, 2024
Via
ACCESSWIRE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
June 12, 2024
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
Via
ACCESSWIRE
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV
June 04, 2024
Via
AB Newswire
Exposures
Product Safety
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
May 29, 2024
Via
ACCESSWIRE
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
May 28, 2024
Via
ACCESSWIRE
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
April 08, 2024
Via
ACCESSWIRE
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
May 23, 2024
Via
ACCESSWIRE
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
May 09, 2024
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
April 29, 2024
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
April 22, 2024
Via
ACCESSWIRE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
April 18, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.